Resource use, costs, and utility estimates for patients with cystic fibrosis with mild impairment in lung function: Analysis of data collected alongside a 48-week multicenter clinical trial

Value in Health

Volumn 15, Issue 2, 2012, Pages 277-283

  DeWitt, Esi Morgan ^a   Grussemeyer, Chelsea A ^b   Friedman, Joëlle Y ^b   Dinan, Michaela A ^b   Lin, Li ^b   Schulman, Kevin A ^b,c   Reed, Shelby D ^b,c  

^a CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER   (United States)

^b DUKE CLINICAL RESEARCH INSTITUTE   (United States)

^c DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

costs and cost analysis; cystic fibrosis; denufosol

Indexed keywords

ANTIBIOTIC AGENT; DENUFOSOL; DORNASE ALFA; PANCREAS ENZYME; TOBRAMYCIN;

ABSENTEEISM; ADOLESCENT; ADULT; ANTIBIOTIC THERAPY; ARTICLE; BACTERIAL COLONIZATION; CHILD; COST OF ILLNESS; COST UTILITY ANALYSIS; CYSTIC FIBROSIS; DATA ANALYSIS; DISEASE SEVERITY; DRUG WITHDRAWAL; EMERGENCY WARD; FEMALE; HEALTH CARE COST; HOME CARE; HUMAN; LUNG FUNCTION; MAJOR CLINICAL STUDY; MALE; MEDICARE; OUTPATIENT CARE; PATIENT CARE; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; TREATMENT DURATION; UNSPECIFIED SIDE EFFECT;

ADOLESCENT; CHILD; COSTS AND COST ANALYSIS; CYSTIC FIBROSIS; DEOXYCYTOSINE NUCLEOTIDES; FEMALE; HEALTH CARE COSTS; HEALTH RESOURCES; HUMANS; LUNG; MALE; MULTIVARIATE ANALYSIS; OUTCOME ASSESSMENT (HEALTH CARE); RESPIRATORY FUNCTION TESTS; UNITED STATES; URIDINE; YOUNG ADULT;

EID: 84858688407     PISSN: 10983015     EISSN: 15244733     Source Type: Journal    
DOI: 10.1016/j.jval.2011.11.027     Document Type: Article

References (33)

1. Johnson C, Butler SM, Konstan MW, et al. Factors influencing outcomes in cystic fibrosis: a center-based analysis. Chest 2003;123: 20-7. (Pubitemid 36126709)
2. Flume PA, O'Sullivan BP, Robinson KA, et al. Cystic fibrosis pulmonary guidelines: chronic medications for maintenance of lung health. Am J Respir Crit Care Med 2007;176:957-69. (Pubitemid 350127838)
3. Cystic Fibrosis Foundation. Cystic Fibrosis Foundation Annual Report 2008. Bethesda, MD: Cystic Fibrosis Foundation, 2008.
4. Konstan MW, Butler SM, Schidlow DV, et al. Patterns of medical practice in cystic fibrosis, Part I: evaluation and monitoring of health status of patients. Investigators and Coordinators of the Epidemiologic Study of Cystic Fibrosis. Pediatr Pulmonol 1999;28:242-7. (Pubitemid 29468457)
5. Konstan MW, Butler SM, Schidlow DV, et al. Patterns of medical practice in cystic fibrosis, Part II: use of therapies. Investigators and Coordinators of the Epidemiologic Study of Cystic Fibrosis. Pediatr Pulmonol 1999;28:248-54.
6. Flume PA, Robinson KA, O'Sullivan BP, et al. Cystic fibrosis pulmonary guidelines: airway clearance therapies. Respir Care 2009;54:522-37.
7. Tiddens HA, Donaldson SH, Rosenfeld M, Paré PD. Cystic fibrosis lung disease starts in the small airways: can we treat it more effectively? Pediatr Pulmonol 2010;45:107-17.
8. Konstan MW, Morgan WJ, Butler SM, et al. Risk factors for rate of decline in forced expiratory volume in one second in children and adolescents with cystic fibrosis. J Pediatr 2007;151:134-9.
9. Accurso FJ, Moss RB, Wilmott RW, et al, Denufosol tetrasodium in patients with cystic fibrosis and normal to mildly impaired lung function. Am J Respir Crit Care Med 2011;183:627-34.
10. Inspire Pharmaceuticals. Inspire announces results of second phase 3 trial with denufosol for cystic fibrosis [press release]. Available from: http://ir.inspirepharm.com/phoenix.zhtml?c=120779&p=irol-news Article&ID=1511789. [Accessed February 10, 2011].
11. Marshall DA, Hux M. Design and analysis issues for economic analysis alongside clinical trials. Med Care 2009;47(7, Suppl. 1):S14 -20.
12. Furlong WJ, Feeny DH, Torrance GW, Barr RD. The Health Utilities Index (HUI) system for assessing health-related quality of life in clinical studies. Ann Med 2001;33:375-84. (Pubitemid 32675379)
13. Yi MS, Britto MT, Wilmott RW, et al. Health values of adolescents with cystic fibrosis. J Pediatr 2003;142:133-40. (Pubitemid 36232901)
14. Horsman J, Furlong W, Feeny D, Torrance G. The Health Utilities Index (HUI): concepts, measurement properties and applications. Health Qual Life Outcomes 2003;1:54.
15. US Department of Labor, Bureau of Labor Statistics. Consumer price index-all urban consumers. US Medical Care. Available from: http:// data.bls.gov/cgi-bin/surveymost?cu. [Accessed July 16, 2010].
16. 2008 Drug Topic Red Book (112 ed.). Montvale, NJ: Thomson Healthcare, 2008.
17. US Centers for Medicare & Medicaid Services. 2009 Physician Fee Schedule. Available from: http://www.cms.hhs.gov/PhysicianFee Sched/PFSNPAF/list.asp. [Accessed July 16, 2010].
18. Bamezai A, Melnick G. Marginal cost of emergency department outpatient visits: an update using California data. Med Care 2006;44: 835-41. (Pubitemid 44306389)
19. US Centers for Medicare & Medicaid Services. Home Health Prospective Payment System (HH PPS) refinement and rate update for calendar year (CY) 2008. Available from: https://www.cms.gov/ transmittals/downloads/R1443CP.pdf. [Accessed July 16, 2010].
20. Dinan M, Morgan DeWitt E, Grussemeyer C, Reed SD. Comparison of inpatient cost estimation methods using data from a cystic fibrosis trial. Value Health 2009;12:A7.
21. Healthcare Cost and Utilization Project. Overview of the Nationwide Inpatient Sample (NIS) Available from: http://www.hcup-us.ahrq.gov/ nisoverview.jsp. [Accessed July 16, 2010].
22. US Department of Labor, Bureau of Labor Statistics. Employer costs for employee compensation. 2008. Available from: http://www.bls.gov/ news.release/archives/ecec-09102008.pdf. [Accessed July 16, 2010].
23. Dray X, Kanaan R, Bienvenu T, et al. Malnutrition in adults with cystic fibrosis. Eur J Clin Nutr 2005;59:152-4. (Pubitemid 40104092)
24. Manning WG, Mullahy J. Estimating log models: to transform or not to transform? J Health Econ 2001;20:461-94. (Pubitemid 32515166)
25. Lieu TA, Ray GT, Farmer G, Shay GF. The cost of medical care for patients with cystic fibrosis in a health maintenance organization. Pediatrics 1999;103:e72.
26. Evidence for Policy and Practice Information and Co-ordinating Centre, University of London. CCEMG-EPPI-Centre cost converter. Available from: http://eppi.ioe.ac.uk/costconversion/default.aspx. [Accessed December 3, 2010].
27. Baumann U, Stocklossa C, Greiner W, et al. Cost of care and clinical condition in paediatric cystic fibrosis patients. J Cyst Fibros 2003;2: 84-90. (Pubitemid 36814095)
28. Krauth C, Jalilvand N, Welte T, Busse R. Cystic fibrosis: cost of illness and considerations for the economic evaluation of potential therapies. Pharmacoeconomics 2003;21:1001-24. (Pubitemid 37255455)
29. Horvais V, Touzet S, François S, et al. Cost of home and hospital care for patients with cystic fibrosis followed up in two reference medical centers in France. Int J Technol Assess Health Care 2006;22:525-31. (Pubitemid 44622975)
30. Kraynack NC, Gothard MD, Falletta LM, McBride JT. Approach to treating cystic fibrosis pulmonary exacerbations varies widely across US CF care centers. Pediatr Pulmonol 2011;46:870-81.
31. Mansley EC, Carroll NV, Chen KS, et al. Good research practices for measuring drug costs in cost-effectiveness analyses: a managed care perspective: the ISPOR Drug Cost Task Force report, Part III. Value Health 2010;13:14-7.
32. The Takeda Prescription Drug Benefit Cost & Plan Design Survey Report: 2008-2009 Edition. Scottsdale, AZ: Pharmacy Benefit Management Institute, Inc., 2008.
33. Olesen HV, Pressler T, Hjelte L, et al. Gender differences in the Scandinavian cystic fibrosis population. Pediatr Pulmonol 2010;45: 959-65.